Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384111 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT00384111 is a Phase 3 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT00384111, a Phase 3 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP. The two patient groups will be compared to determine if Zevalin given after R-CVP therapy provides greater benefits than receiving no additional anti-cancer therapy after R-CVP.
Interventions
- DRUG R-CVP
- DRUG Zevalin Therapeutic Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384111
The ClinicalTrials.gov registry entry for NCT00384111 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which R-CVP is the first listed.
NCT00384111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384111 about?
NCT00384111 is a clinical study titled "Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)". This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP. The two patient groups will be compared to determine if Zevalin given after R-CVP therapy provides...
What is the current status of trial NCT00384111?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2006-10. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00384111?
The interventions under investigation include: R-CVP (DRUG), Zevalin Therapeutic Regimen (DRUG).
Who is sponsoring clinical trial NCT00384111?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.